Zealand Pharma (ZEAL)
17.59
0.00 (0.00%)
Latest Headlines
Zealand Pharma's petrelintide shows weight loss in Type 2 diabetes trial
October 7, 2026 1:14 PM - StreetInsider
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
October 7, 2026 1:14 PM - StreetInsider
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
October 5, 2026 12:30 PM - StreetInsider
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
October 1, 2026 9:30 AM - StreetInsider
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and
October 1, 2026 3:30 AM - StreetInsider
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
September 30, 2026 4:00 PM - StreetInsider
Zealand Pharma publishes Phase 2 petrelintide trial results in The Lancet
September 29, 2026 6:03 PM - StreetInsider
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
September 29, 2026 6:03 PM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
September 28, 2026 11:00 AM - StreetInsider
Zealand Pharma starts Phase 3 trials for obesity drug petrelintide
September 22, 2026 11:00 AM - StreetInsider
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
September 22, 2026 11:00 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
September 21, 2026 11:00 AM - StreetInsider
Zealand Pharma gets EU recommendation for short bowel syndrome drug
September 18, 2026 6:11 AM - StreetInsider
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
September 18, 2026 6:11 AM - StreetInsider
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
September 15, 2026 7:00 AM - BizWire
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
September 14, 2026 11:00 AM - StreetInsider
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
September 10, 2026 11:00 AM - StreetInsider
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 9, 2026 11:00 AM - StreetInsider
Barclays Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Equalweight
September 8, 2026 2:48 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
September 7, 2026 11:00 AM - StreetInsider
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
September 2, 2026 11:00 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
August 31, 2026 11:00 AM - StreetInsider
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 28, 2026 4:00 PM - Globe NewsWire
Zealand Pharma – Notification of holding of treasury shares
August 24, 2026 11:05 AM - Globe NewsWire
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
August 24, 2026 11:00 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
August 17, 2026 11:00 AM - StreetInsider
Zealand Pharma Announces Financial Results for the First Half of 2026
August 13, 2026 1:00 AM - StreetInsider
Zealand Pharma sells rusfertide royalty rights to Royalty Pharma for $100M
August 12, 2026 4:07 PM - StreetInsider
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
August 12, 2026 4:05 PM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
August 10, 2026 11:00 AM - StreetInsider
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
August 6, 2026 11:00 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
August 3, 2026 11:00 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
July 27, 2026 11:00 AM - StreetInsider
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
July 20, 2026 4:00 PM - StreetInsider
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
July 20, 2026 11:00 AM - StreetInsider
Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold
July 14, 2026 1:58 AM - StreetInsider
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
July 13, 2026 11:00 AM - StreetInsider
Full Article List
